Relmada Therapeutics (STU:4E2) ROE % Adjusted to Book Value : -77.11% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics ROE % Adjusted to Book Value?

Relmada Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -156.54%. Relmada Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 2.03. Relmada Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -77.11%.

Relmada Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Relmada Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics ROE % Adjusted to Book Value Chart

Relmada Therapeutics Annual Data

Trend

Aug13

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-22.24

-28.91

-126.45

-66.10

Relmada Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-96.16	-82.25	-57.89	-73.79	-77.11

Competitive Comparison of Relmada Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Relmada Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's ROE % Adjusted to Book Value falls into.

Relmada Therapeutics ROE % Adjusted to Book Value Calculation

Relmada Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-85.93%	/	1.30
	=	-66.10%

Relmada Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-156.54%	/	2.03
	=	-77.11%

Relmada Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

RLMD:USA

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines